《公司業績》維他奶(00345.HK)半年純利6.72億元升26% 中期息維持3.8仙
維他奶國際(00345.HK)公布截至今年9月底止中期業績,營業額44.1億元,按年跌5.9%。純利6.72億元,按年升26%;每股盈利63.1仙。派中期息3.8仙,按年持平。
期內,毛利為24.1億元,按年下跌6%,主要由於銷量減少。經營溢利按年上升28.7%至9.29億元,主因適時謹慎成本控制,根據疫情發展而更改分階段投資的計劃,以及疫情期間某些市場當地政府給予的補貼。撇除政府補貼,經營溢利增長10%。EBITDA則增加27%至11.52億元,主要由於經營費用減少加上獲得政府補貼所致。
另外,期內毛利率維持55%,主要由於政府補貼,但部分被原材料(尤其是糖及奶粉)的不利價格所抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.